This Breakout Healthcare Growth Stock Is Too Cheap to Miss

This Breakout Healthcare Growth Stock Is Too Cheap to Miss
·4 min read

Before the pandemic, Fulgent Genetics (NASDAQ: FLGT) was a little-known genetic testing business with grand ambitions but limited means. Let's take a brief walk through Fulgent Genetics' business and the inexpensive valuation of its shares to see if it might be a good fit for your portfolio in 2022. The bottom line with Fulgent Genetics is that the company's early pandemic pivot into providing coronavirus testing has built strong financial and logistical foundations that it can now use to grow with abandon.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting